Category: Street Authority
Related News
2 New Stock Ideas from a Guy who’s Beat Wall Street for 15 Years Running How to Earn Thousands in Extra Income Every Month If You Are Bearish On the Economy, Then You Need To Own This Stock Almost Every Oil Well Will Need This Company’s Technology These Stocks Yield Up to 13.5%… But I Doubt You Know About Them You Can’t Afford To Pass On This Stock A Powerhouse Investor Is Targeting this Controversial Stock The Market Could Tumble Very Soon — Here’s How to Protect Your Portfolio The Market is WRONG About this Big Pharma Stock |
Recent News
|
It's that time of year again, when investment managers are required to disclose their fund's holdings to the SEC, and by extension, to all investors. And for most investment companies and hedge funds, it's a pretty straight-forward process... just make a list of all the stocks you own, and how much of them you own.If you're Greenlight Capital's David Einhorn, however, it's not quite that simple.
I've discovered a way to earn the equivalent of a second Social Security check every month.
Now, I don't want to mislead you. This check isn't from Uncle Sam. In fact, the government doesn't have anything to do with it. (I think that's good news considering all the debt problems the government is facing).
And you won't be receiving one big check. Instead, you'll see dozens of smaller ones in your mailbox -- or brokerage account -- each month.
Trading is in my blood. I vividly remember, as an elementary school student, trading baseball cards with my classmates. My trading interest blossomed as I learned how to buy low and sell high via various part-time business endeavors. These businesses included selling produce I got for free from my grandparent's garden door-to-door and a real estate publishing/marketing company. This interest led me to major in business/economics in college.
Investors looking at energy stocks may have a bit of whiplash these days. Oil prices appear fairly firm while natural gas prices still remain near multi-year lows. In other countries, natural gas prices are surging, as demand rises in places that have de-commissioned nuclear power plants, such as Japan and Germany.
Here at StreetAuthority, we take a much broader view of oil, gas, coal, nuclear and many other commodities.
My husband Melvin and I bought our first home when we were expecting our first child. After an exhaustive search, we settled on an up-and-down duplex. It was built in the 1940s and had a rental suite in the basement.
The purchase was a good decision from a financial standpoint. Rental payments covered a substantial part of our mortgage, and about two years later we were able to sell it for 20% more than we paid.
In this low interest rate environment, investors have turned to high-yielding blue-chips as a source of retirement income. This five-part series will outline what I believe to be the top five dividend aristocrat stocks, most suitable for a retiree's portfolio.
In my previous articles on dividend aristocrats, I told you about paper-products manufacturer Kimberly-Clark (NYSE: KMB) and Emerson Electric (NYSE: EMR), which focuses on electrical-power solutions for consumers and industry.
What on Earth is Steven A. Cohen thinking? He's authorized traders at his investment firm, SAC Capital, to quickly build a large position in Accretive Health (NYSE: AH). Roughly a week ago, SAC announced that it had already bought so many shares that it now owns 5% of the company. Is Cohen crazy? After all, Accretive has seen its shares plunge after a fairly nasty lawsuit was filed by Minnesota's Attorney General.
Make no mistake, Cohen is no fool.
To Europe's leaders and Greek voters, here's a modest request: Will you please flip over all the cards and make the bold moves that markets are increasingly expecting? At this point, providing further bailout funds for Greece is simply foolish. No amount of money can turn this economy around as long as it's still tied to the euro and undergoing deep austerity measures.
Generic prescription drugs are the bane of big pharmaceutical companies and investors alike. As patents for name brand drugs expire, generics eat into revenue, shrink earnings, and depress stock prices of the Big Pharma players.
But the smart investor knows that good drug companies are hardly one-trick ponies. The herd always overlooks the mountains of products that either still have patent protection, or have survived and retained market share.